Evaluation of alendronate in prevention of steroid- induced osteopenia in childhood ALL and NHL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201202279155N1

Enrollment

Registered

2012-03-24

Start date

2012-04-03

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Acute lymphoblastic leukaemia. Condition 2: Non-Hodgkin lymphoma. Condition 3: osteoprosis. Acute lymphoblastic leukaemia Non-Hodgkin lymphoma, unspecified Drug-induced osteoporosis

Interventions

Intervention 1: case: cap alenderonate 35 mg/ week for 6 months. Intervention 2: control group: without treatment.

Treatment - Drugs

case: cap alenderonate 35 mg/ week for 6 months

control group: without treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: inclusion criteria: children with ALL or NHL; informed consent form exclusion criteria: Patient or parents desire to leave the study; Non-compliance with treatment regimen

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
BMD. Timepoint: 0, 6months after drug administration. Method of measurement: Bone densitometery of neck of femur and spins.	—

Secondary

Measure	Time frame
Sever allergic reaction. Timepoint: every week. Method of measurement: history and physical examination.;Gastro intestinl problems. Timepoint: every week. Method of measurement: history and physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Afsane Akhondzadeh

Arak University of Medical Scienses

akhondzadeh@arakmu.ac.ir+98 86 1223 5605

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026